The Center for Advanced Reproductive Services (CARS) in Farmington, Connecticut, is deploying Embryo Predict, a federally cleared artificial intelligence system for embryo assessment during in vitro fertilization (IVF), within its microscope lab.

Alife Health developed Embryo Predict and is rolling it out across First Fertility, a leading national fertility network, for microscope labs network-wide. CARS is the first center to launch it, with more centers implementing soon.

CARS operates fertility clinics in Farmington, Hartford, New London, and Middlebury, Connecticut, and Western Massachusetts. It is an academic affiliate of the University of Connecticut School of Medicine, holds Center of Excellence status within First Fertility, and hosts the university's Reproductive Endocrinology and Infertility fellowship. The center handles 1,300 patient visits and 950 IVF retrievals annually, contributing to more than 13,000 births.

Embryo Predict analyzes microscope images of Day 5, 6, and 7 blastocyst-stage embryos and generates a data-driven score to guide transfer decisions. It was validated in a randomized controlled trial and holds clearance from the Food and Drug Administration (FDA) and a CE Mark.

The tool's clinical evidence factored into First Fertility's decision to expand its use.

Dr. Alison Bartolucci, Chief Scientific Officer of First Fertility, said, "The best innovations strengthen clinical expertise. Embryo Predict is backed by rigorous clinical evidence, and our pilot experience confirmed its value. We are pleased to begin introducing this technology at First Fertility Centers to support our embryologists and the patients they serve."

That growing adoption reflects momentum across the field.

"We're thrilled to see First Fertility becoming the second major network to deploy Embryo Predict," said Melissa Teran, CEO of Alife. "That rapid adoption from leading practices is real validation of the clinical evidence and shows momentum is building in how the field approaches embryo assessment."